Innoviva Inc

XNAS:INVA

17.71

-0.55 (-3.01%)

4:10:04 PM EDT: $17.71 0.00 (0.00%)

Market Cap (Intraday)	1.08B
Current PE	28.01
Forward PE	15.54
2yr Forward PE	8.2

See more stats

Estimates Current Quarter

Revenue	$91.36 Million
Adjusted EPS	$0.46

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Innoviva Inc Stock, XNAS:INVA

1350 Old Bayshore Highway, Suite 400, Burlingame, California 94010

United States of America

Phone: +1.650.238.9600

Number of Employees: 127

http://www.inva.com

Description

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.